Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-65c3d51a8623ae84242075e46df738cd",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-65c3d51a8623ae84242075e46df738cd",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-65c3d51a8623ae84242075e46df738cd",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-65c3d51a8623ae84242075e46df738cd\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-65c3d51a8623ae84242075e46df738cd</b></p><a name=\"composition-en-65c3d51a8623ae84242075e46df738cd\"> </a><a name=\"hccomposition-en-65c3d51a8623ae84242075e46df738cd\"> </a><a name=\"composition-en-65c3d51a8623ae84242075e46df738cd-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1336/001 [8 mg buprenorphine/0.16 mL]</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - buvidal</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/18/1336/001 [8 mg buprenorphine/0.16 mL]"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp65c3d51a8623ae84242075e46df738cd"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - buvidal",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Buvidal is and what it is used for</li><li>What you need to know before you receive Buvidal</li><li>How Buvidal is given</li><li>Possible side effects</li><li>How to store Buvidal</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What buvidal is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What buvidal is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Buvidal contains the active substance buprenorphine, which is a type of opioid medicine. It is used to treat opioid dependence in patients who are also receiving medical, social and psychological support. Buvidal is intended for use in adults and adolescents aged 16 years or over.</p></div>"
}
},
{
"title" : "2. What you need to know before you take buvidal",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take buvidal"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>You must not receive Buvidal</p><ul><li>if you are allergic to buprenorphine or any of the other ingredients of this medicine (listed in section 6)</li><li>if you have serious breathing problems</li><li>if you have serious liver problems</li><li>if you are intoxicated with alcohol or have trembling, sweating, anxiety, confusion or hallucinations caused by alcohol.</li></ul><p>Warnings and precautions</p><p>Talk to your doctor before receiving Buvidal if you have:</p><ul><li>asthma or other breathing problems</li><li>any liver disease such as hepatitis</li><li>severe kidney impairment</li><li>certain heart rhythm conditions (long QT syndrome or prolonged QT interval)</li><li>low blood pressure</li><li>recently suffered a head injury or brain disease</li><li>a urinary disorder (especially linked to enlarged prostate in men)</li><li>thyroid problems</li><li>an adrenocortical disorder (e.g. Addison s disease)</li><li>gall bladder problems</li><li>depression or other conditions that are treated with antidepressants.<br/>The use of these medicines together with Buvidal can lead to serotonin syndrome, a potentially life-threatening condition (see Other medicines and Buvidal )</li><li>if you have ever had an allergic reaction to latex.</li></ul><p>Important things to be aware of</p><ul><li>Breathing problems: Some people have died from very slow or shallow breathing caused by taking buprenorphine with other central nervous system depressants (substances that slow down some brain activity) such as benzodiazepines, alcohol or other opioids.</li><li>Drowsiness: This medicine may cause drowsiness especially when used with alcohol or other central nervous system depressants (substances that slow down some brain activity) such as benzodiazepines, other medicines that reduce anxiety or cause sleepiness, pregabalin or gabapentin.</li><li>Dependence: This medicine can cause dependence.</li><li>Liver damage: Liver damage can occur with buprenorphine, especially when it is misused. It can also occur because of viral infections (chronic hepatitis C), alcohol abuse, anorexia (eating disorder) or use of other medicines which harm your liver. Your doctor may ask you to have regular blood tests to check your liver. Tell your doctor if you have any liver problems before you start treatment with Buvidal.</li><li>Withdrawal symptoms: This medicine can cause withdrawal symptoms if you take it less than 6 hours after you use a short-acting opioid (e.g. morphine, heroin) or less than 24 hours after you use a long-acting opioid such as methadone.</li><li>Blood pressure: This medicine may cause your blood pressure to drop suddenly, causing you to feel dizzy if you get up too quickly from sitting or lying down.</li><li>Diagnosis of unrelated medical conditions: This medicine may mask pain and make it difficult to diagnose some diseases. Do not forget to tell your doctor that you are being treated with this medicine.</li><li>Sleep-related breathing disorders: Buvidal can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor.</li></ul><p>Children and adolescents</p><p>Buvidal is not for use in children below 16 years of age. You will be more closely monitored by your doctor if you are an adolescent (16-17 years old).</p><p>Other medicines and Buvidal</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines. Some medicines may increase the side effects of Buvidal and may cause very serious reactions.</p><p>It is especially important to tell your doctor if you are taking:</p><ul><li>benzodiazepines (used to treat anxiety or sleep disorders). Taking too much of a benzodiazepine together with Buvidal may lead to death because both medicines can cause very slow and shallow breathing (respiratory depression). If you need a benzodiazepine, your doctor will prescribe the correct dose.</li><li>gabapentinoids (gabapentin or pregabalin) (used to treat epilepsy or neuropathic pain). Taking too much of a gabapentinoid may lead to death because both medicines can cause very slow and shallow breathing (respiratory depression). You must use the dose that your doctor has prescribed for you.</li><li>alcohol or medicines containing alcohol. Alcohol can worsen the sedative effect of this medicine.</li><li>other medicines that may make you feel sleepy which are used to treat illnesses such as anxiety, sleeplessness, convulsions (fits) and pain. These medicines when taken together with Buvidal can slow down some brain activity and reduce alertness and how well you will drive and use machines. Examples of medicines that can make you feel sleepy or less alert include:</li></ul><ul><li>other opioids such as methadone, certain painkillers and cough medicines. These medicines may also increase the risk of opioid overdose</li><li>antidepressants (used to treat depression)</li><li>sedative antihistamines (used to treat allergic reactions)</li><li>barbiturates (used to cause sleep or sedation)</li><li>certain anxiolytics (used to treat anxiety disorders)</li><li>antipsychotics (used to treat psychiatric disorders such as schizophrenia)</li><li>clonidine (used to treat high blood pressure).</li></ul><ul><li>opioid painkillers. These medicines may not work properly when taken together with Buvidal and they may increase the risk of overdose.</li><li>naltrexone and nalmefene (used to treat addiction disorders) as they can stop Buvidal from working properly. You should not take them at the same time as this medicine.</li><li>certain antiretrovirals (used to treat HIV infection) such as ritonavir, nelfinavir or indinavir as they may increase the effects of this medicine.</li><li>certain antifungal medicines (used to treat fungal infections) such as ketoconazole, itraconazole as they may increase the effects of this medicine.</li><li>macrolide antibiotics (used to treat bacterial infections) such as clarithromycin and erythromycin as they may increase the effects of this medicine.</li><li>certain antiepileptic medicines (used to treat epilepsy) such as phenobarbital, carbamazepine and phenytoin as they may decrease the effect of Buvidal.</li><li>rifampicin (used to treat tuberculosis). Rifampicin may decrease the effect of Buvidal.</li><li>monoamine oxidase inhibitors (used to treat depression) such as phenelzine, isocarboxazid, iponiazid and tranylcypromine as they may increase the effects of this medicine.</li><li>anti-depressants such as moclobemide, tranylcypromine, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, amitriptyline, doxepine, or trimipramine. These medicines may interact with Buvidal and you may experience symptoms such as involuntary, rhythmic contractions of muscles, including the muscles that control movement of the eye, agitation, hallucinations, coma, excessive sweating, tremor, exaggeration of reflexes, increased muscle tension, body temperature above 38 C. Contact your doctor when experiencing such symptoms.</li></ul><p>Buvidal with alcohol</p><p>Do not take alcohol while using Buvidal, (see section 2 warnings and precautions). Taking alcohol with this medicine may increase drowsiness and may increase the risk of breathing problems.</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may become pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine. The risks of using Buvidal in pregnant women are not known. Your doctor will help you decide if you should continue taking the medicine during pregnancy. Using this medicine during late pregnancy may cause drug withdrawal symptoms including breathing problems in your new-born baby. This may happen from several hours to several days after birth.</p><p>Check with your doctor before using Buvidal during breastfeeding as this medicine passes into breast milk.</p><p>Driving and using machines</p><p>Buvidal may make you sleepy and dizzy. This is more likely at the start of treatment and when your dose is being changed. These effects can be worse if you drink alcohol or take other sedative medicines. Do not drive, use any tools or machines, or perform dangerous activities until you know how this medicine affects you.</p><p>Buvidal contains alcohol</p><p>Buvidal 8 mg, 16 mg, 24 mg and 32 mg contain 95.7 mg of alcohol (ethanol) in each mL (10% w/w). The amount in 1 dose of this medicine is equivalent to less than 2 mL beer or 1 mL wine. The small amount of alcohol in this medicine will not have any noticeable effects.</p></div>"
}
},
{
"title" : "3. How to take buvidal",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take buvidal"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Buvidal must be given by healthcare professionals only.</p><p>Buvidal 8 mg, 16 mg, 24 mg and 32 mg are given weekly. Buvidal 64 mg, 96 mg, 128 mg and 160 mg are given monthly.</p><p>Your doctor will determine the best dose for you. During your treatment, the doctor may adjust the dose, depending on how well the medicine works.</p><p>Starting treatment The first dose of Buvidal will be given to you when you show clear signs of withdrawal.<br/>If you are dependent on short-acting opioids (e.g. morphine or heroin), the first dose of Buvidal will be given to you at least 6 hours after you last used an opioid. If you are dependent on long-acting opioids (e.g. methadone), your dose of methadone will be reduced to below 30 mg per day before beginning with Buvidal. The first dose of this medicine will be given to you at least 24 hours after you last used methadone.</p><p>If you are not already receiving sublingual (under the tongue) buprenorphine (the same active substance as in Buvidal), the recommended starting dose is 16 mg, with one or two additional Buvidal 8 mg doses given at least 1 day apart during the first treatment week. This means a target dose of 24 mg or 32 mg during the first treatment week. If you have not used buprenorphine before you will receive a 4 mg sublingual buprenorphine dose and be observed for an hour before the first Buvidal dose.</p><p>Buvidal for monthly treatment can be used, if appropriate for you, once stabilisation has been achieved with Buvidal for weekly treatment (four weeks treatment or more, where practical).</p><p>If you are already taking sublingual buprenorphine, you can start receiving Buvidal the day after your last treatment. Your doctor will prescribe the correct starting dose of Buvidal for you depending on the dose of sublingual buprenorphine you are now taking.</p><p>Continuing treatment and dose adjustment During continued treatment with Buvidal, your doctor may decrease or increase your dose according to your need. You may be switched from weekly and monthly treatment and from monthly to weekly treatment. Your doctor will prescribe the correct dose for you. During continued treatment, you might receive one additional Buvidal 8 mg dose between your weekly or monthly treatments if your doctor thinks this is appropriate for you. The maximum dose per week if you are on weekly Buvidal treatment is 32 mg with an additional 8 mg dose. The maximum dose per month if you are on monthly Buvidal treatment is 160 mg.</p><p>Route of administration Buvidal is given as a single injection under the skin (subcutaneously) in any of the allowed injection areas buttock, thigh, abdomen or upper arm. You can receive several injections in the same injection area, but the exact injection sites will be different for each weekly and monthly injection for a minimum period of 8 weeks.</p><p>If you use more buprenorphine than you should</p><p>If you have received more buprenorphine than you should you need to contact your doctor immediately since this can cause very slow and shallow breathing which can lead to death.</p><p>If you use too much buprenorphine, you must immediately seek medical attention as overdose may cause serious and life-threatening breathing problems. Symptoms of overdose may include breathing more slowly and weakly, feeling more sleepy than normal, feeling sick, vomiting and/or having slurred speech or difficulty talking. You may also have smaller pupils. If you start to feel faint, this may be a sign of low blood pressure.</p><p>If you miss a dose of Buvidal</p><p>It is very important to keep all your appointments to receive Buvidal. If you miss an appointment, ask your doctor when to schedule your next dose.</p><p>If you stop using Buvidal</p><p>Do not stop treatment without checking with the doctor who is treating you. Stopping treatment may cause withdrawal symptoms. If you have any further questions on the use of this product, ask your doctor.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately or get urgent medical attention if you have side effects such as:</p><ul><li>sudden wheezing, difficulty breathing, swelling of the eyelids, face, tongue, lips, throat or hands; rash or itching especially over your whole body. These may be signs of a life-threatening allergic reaction.</li><li>if you start to breathe more slowly or weakly than usual (respiratory depression).</li><li>if you start to feel faint, as this may be a sign of low blood pressure.</li></ul><p>Also tell your doctor immediately if you get side effects such as:</p><ul><li>severe tiredness, have no appetite or if your skin or eyes look yellow. These may be symptoms of liver damage.</li></ul><p>Other side effects: Very common side effects (may affect more than 1 in 10 people):</p><ul><li>Insomnia (inability to sleep)</li><li>Headache</li><li>Nausea (feeling sick)</li><li>Sweating, drug withdrawal syndrome, pain.</li></ul><p>Common side effects (may affect up to 1 in 10 people):</p><ul><li>Infection, influenza, sore throat and painful swallowing, runny nose</li><li>Swollen glands (lymph nodes)</li><li>Hypersensitivity</li><li>Decreased appetite</li><li>Anxiety, agitation, depression, hostility, nervousness, abnormal thinking, paranoia</li><li>Sleepiness, feeling dizzy, migraine, burning or tingling in hands and feet, fainting, tremor, increase in muscle tension, speech disorders</li><li>Watery eyes, abnormal widening or narrowing of the pupil (the dark part of the eye)</li><li>Palpitations</li><li>Low blood pressure</li><li>Cough, shortness of breath, yawning, asthma, bronchitis</li><li>Constipation, vomiting (being sick), belly pain, flatulence (wind), indigestion, dry mouth, diarrhoea</li><li>Rash, itching, hives</li><li>Joint pain, back pain, muscle pain, muscle spasms, neck pain, bone pain</li><li>Painful period</li><li>Injection site reactions e.g. pain, itching, red skin, swelling and hardening of skin, swelling of the ankles, feet or fingers, weakness, feeling unwell, fever, chills, drug withdrawal syndrome in the new-born, chest pain</li><li>Abnormal liver test results.</li></ul><p>Uncommon side effects (may affect up to 1 in 100 people):</p><ul><li>Skin infection at the injection site</li><li>A feeling of dizziness or spinning (vertigo).</li></ul><p>Not known (frequency cannot be estimated from the available data):</p><ul><li>Hallucinations, feeling happiness and excitement (euphoria)</li><li>Abnormal redness of the skin</li><li>Painful or difficult urination</li><li>Injection site reactions e.g. open sores, a swollen area with collected pus, and death of cells or tissue at the injection site.</li></ul><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store buvidal",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store buvidal"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Buvidal is for administration of healthcare professionals only. Take-home use or self-administration of the product by patients is not allowed. Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton or the syringe label after EXP. The expiry date refers to the last day of that month. Do not refrigerate or freeze. Do not use this medicine if you notice visible particles or if it is cloudy. Buvidal is for single use only. Any used syringe should be discarded.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Buvidal contains</p><ul><li>The active substance is buprenorphine</li><li>The other ingredients are soybean phosphatidylcholine, glycerol dioleate, ethanol anhydrous (see section 2 Buvidal contains alcohol) (only in weekly formulation) and N-methylpyrrolidone (only in monthly formulation).</li></ul><p>The following syringes are available:</p><p>Weekly injection: 8 mg: Pre-filled syringe containing 8 mg buprenorphine in 0.16 mL solution 16 mg: Pre-filled syringe containing 16 mg buprenorphine in 0.32 mL solution 24 mg: Pre-filled syringe containing 24 mg buprenorphine in 0.48 mL solution 32 mg: Pre-filled syringe containing 32 mg buprenorphine in 0.64 mL solution</p><p>Monthly injection: 64 mg: Pre-filled syringe containing 64 mg buprenorphine in 0.18 mL solution 96 mg: Pre-filled syringe containing 96 mg buprenorphine in 0.27 mL solution 128 mg: Pre-filled syringe containing 128 mg buprenorphine in 0.36 mL solution 160 mg: Pre-filled syringe containing 160 mg buprenorphine in 0.45 mL solution</p><p>What Buvidal looks like and contents of the pack</p><p>Buvidal is a prolonged-release solution for injection. Each pre-filled syringe contains a yellowish to yellow clear liquid.</p><p>The following pack sizes are available:<br/>Pre-filled syringes containing 8 mg, 16 mg, 24 mg, 32 mg, 64 mg, 96 mg, 128 mg and 160 mg solution for injection. Each pack contains 1 pre-filled syringe with stopper, needle, needle shield, safety device and 1 plunger rod.</p><p>Marketing Authorisation Holder Camurus AB Ideon Science Park SE-223 70 Lund Sweden <a href=\"mailto:medicalinfo@camurus.com\">medicalinfo@camurus.com</a></p><p>Manufacturer Rechon Life Science AB Soldattorpsv gen 5 216 13 Limhamn Sweden</p><p>This leaflet was last revised in .</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp65c3d51a8623ae84242075e46df738cd",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp65c3d51a8623ae84242075e46df738cd",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp65c3d51a8623ae84242075e46df738cd\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp65c3d51a8623ae84242075e46df738cd</b></p><a name=\"mp65c3d51a8623ae84242075e46df738cd\"> </a><a name=\"hcmp65c3d51a8623ae84242075e46df738cd\"> </a><a name=\"mp65c3d51a8623ae84242075e46df738cd-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1336/001 [8 mg buprenorphine/0.16 mL]</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Buvidal 8 mg prolonged-release solution for injection</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/18/1336/001 [8 mg buprenorphine/0.16 mL]"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Buvidal 8 mg prolonged-release solution for injection",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
